
Trypsin (48mg) + Diclofenac (50mg) + Bromelain (90mg) + Rutoside (100mg)
Active composition
+3 more active ingredients
Diclofenac inhibits COX-1 and COX-2 enzymes, leading to decreased synthesis of prostaglandins, which mediate pain and inflammation.
Bromelain breaks down fibrin and other proteins involved in inflammation, reducing swelling and pain.
Medical applications
Enzogrand-D Tablet is a combination pharmaceutical formulation containing Trypsin 48 mg, Bromelain 90 mg, Rutoside 100 mg, and Diclofenac 50 mg, designed to provide effective anti-inflammatory, analgesic, and fibrinolytic effects. Trypsin and Bromelain are proteolytic enzymes that facilitate the breakdown of proteins, promoting the resolution of inflammation and edema by enhancing fibrinolysis and reducing swelling in acute and chronic inflammatory conditions. Rutoside, a bioflavonoid, acts as a vascular protector by strengthening capillary walls, reducing capillary permeability, and exhibiting antioxidant properties, thereby aiding in the management of microcirculatory disturbances and preventing oxidative tissue damage. Diclofenac, a nonsteroidal anti-inflammatory drug (NSAID), provides potent analgesic and anti-inflammatory effects by inhibiting cyclooxygenase enzymes, thereby reducing the synthesis of prostaglandins responsible for pain and inflammation. The synergistic action of these components makes Enzogrand-D effective in the treatment of musculoskeletal disorders, postoperative inflammation, soft tissue injuries, and conditions involving pain and swelling. This combination therapy offers a comprehensive approach by addressing inflammation, pain, and vascular integrity simultaneously. Enzogrand-D should be used under medical supervision, considering contraindications such as hypersensitivity to NSAIDs, bleeding disorders, and gastrointestinal ulcers.
Dosage information not available. Please consult your doctor or pharmacist.
Important precautions
Based on clinical trials and patient reports.
Overall Tolerance
Common Side Effects
Enzogrand-D Tablet is unsafe to use during pregnancy as there is definite evidence of risk to the developing baby. However, the doctor may rarely prescribe it in some life-threatening situations if the benefits are more than the potential risks. Please consult your doctor.
High Risk
Information regarding the use of Enzogrand-D Tablet during breastfeeding is not available. Please consult your doctor.
Medical Advice
Enzogrand-D Tablet is probably safe to use in patients with kidney disease. Limited data available suggests that dose adjustment of Enzogrand-D Tablet may not be needed in these patients. Please consult your doctor.
Exercise Caution
Enzogrand-D Tablet may cause side effects which could affect your ability to drive. Enzogrand-D Tablet may cause headaches, blurred vision, dizziness or drowsiness in some patients. This may affect your ability to drive.
Consult Doctor
Enzogrand-D Tablet is probably safe to use in patients with liver disease. Limited data available suggests that dose adjustment of Enzogrand-D Tablet may not be needed in these patients. Please consult your doctor.
Regular Checkup
0 reviews for Enzogrand-D Tablet

Trypsin (48mg) + Bromelain (90mg) + Rutoside (100mg) + Diclofenac (50mg)
Cheaper alternative availability
This medicine doesn't have a cheaper alternative with the same composition. Our health advisors can help you find other savings options based on your prescription.
Active composition
+3 more active ingredients
Diclofenac inhibits COX-1 and COX-2 enzymes, leading to decreased synthesis of prostaglandins, which mediate pain and inflammation.
Bromelain breaks down fibrin and other proteins involved in inflammation, reducing swelling and pain.
Medical applications
Enzogrand-D Tablet is a combination pharmaceutical formulation containing Trypsin 48 mg, Bromelain 90 mg, Rutoside 100 mg, and Diclofenac 50 mg, designed to provide effective anti-inflammatory, analgesic, and fibrinolytic effects. Trypsin and Bromelain are proteolytic enzymes that facilitate the breakdown of proteins, promoting the resolution of inflammation and edema by enhancing fibrinolysis and reducing swelling in acute and chronic inflammatory conditions. Rutoside, a bioflavonoid, acts as a vascular protector by strengthening capillary walls, reducing capillary permeability, and exhibiting antioxidant properties, thereby aiding in the management of microcirculatory disturbances and preventing oxidative tissue damage. Diclofenac, a nonsteroidal anti-inflammatory drug (NSAID), provides potent analgesic and anti-inflammatory effects by inhibiting cyclooxygenase enzymes, thereby reducing the synthesis of prostaglandins responsible for pain and inflammation. The synergistic action of these components makes Enzogrand-D effective in the treatment of musculoskeletal disorders, postoperative inflammation, soft tissue injuries, and conditions involving pain and swelling. This combination therapy offers a comprehensive approach by addressing inflammation, pain, and vascular integrity simultaneously. Enzogrand-D should be used under medical supervision, considering contraindications such as hypersensitivity to NSAIDs, bleeding disorders, and gastrointestinal ulcers.
Dosage information not available. Please consult your doctor or pharmacist.
Important precautions
Based on clinical trials and patient reports.
Overall Tolerance
Common Side Effects
Enzogrand-D Tablet is unsafe to use during pregnancy as there is definite evidence of risk to the developing baby. However, the doctor may rarely prescribe it in some life-threatening situations if the benefits are more than the potential risks. Please consult your doctor.
High Risk
Information regarding the use of Enzogrand-D Tablet during breastfeeding is not available. Please consult your doctor.
Medical Advice
Enzogrand-D Tablet is probably safe to use in patients with kidney disease. Limited data available suggests that dose adjustment of Enzogrand-D Tablet may not be needed in these patients. Please consult your doctor.
Exercise Caution
Enzogrand-D Tablet may cause side effects which could affect your ability to drive. Enzogrand-D Tablet may cause headaches, blurred vision, dizziness or drowsiness in some patients. This may affect your ability to drive.
Consult Doctor
Enzogrand-D Tablet is probably safe to use in patients with liver disease. Limited data available suggests that dose adjustment of Enzogrand-D Tablet may not be needed in these patients. Please consult your doctor.
Regular Checkup
0 reviews for Enzogrand-D Tablet











